Elite Pharmaceuticals Inc
ELTP- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001053369
In the last 90 days, Elite Pharmaceuticals Inc insiders filed 1 open-market purchase and 0 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $365 in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Elite Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $8.61K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$8.61K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Elite Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Dash Barry H | Director | 3,265,555 | Sep 10, 2026 | 1 |
| Plassche Douglas | EVP Operations | 6,000,000 | Jan 13, 2026 | 2 |
| Elite Pharmaceuticals Inc | EVP Operations | 4,300,000 | Aug 26, 2025 | 0 |
| Kirkov Kirko | Chief Commercial Officer | 16,366 | Jul 25, 2025 | 0 |
| Hakim Nasrat A | CEO, President | 216,649,250 | Apr 2, 2024 | 0 |
| Whitnell Jeffrey A | Director | 3,187,020 | Nov 27, 2023 | 0 |
| Caskey Davis S | Director | 2,049,436 | Nov 27, 2023 | 0 |
| Chen Robert C J | CFO, Secretary, Treasurer | – | Jul 7, 2022 | 0 |
| Bregman Marc | CFO, Secretary, Treasurer | – | Jul 7, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)1:29 PM ET | Aug 19 | 22 daysLate | Dash Barry HDirector | PPurchase | +30.0K | $0.287 | +$8.61K | +0.9%3.27M after | |
| Oct 3, 2025 (view filing) | Oct 2 | 1 day | Plassche DouglasEVP Operations | SSale | −800.0K | $0.62 | −$496.0K | −18.6%3.50M after | |
| Aug 26, 2025 (view filing)5:17 PM ET | Aug 22 | 4 days | Elite Pharmaceuticals IncEVP Operations | SSale | −500.0K | $0.5243 | −$262.1K | −21.7%1.80M after | |
| Jul 25, 2025 (view filing) | Jul 10 | 15 daysLate | Kirkov KirkoChief Commercial Officer | PPurchase | +16.4K | $0.59 | +$9.66K | New position16.4K after | |
| Jul 10, 2025 (view filing) | Jul 8 | 2 days | Plassche DouglasEVP Operations | SSaleStock Options (right to buy) | −200.0K | $0.58 | −$116.0K | −8.0%2.30M after | |
| Oct 28, 2024 (view filing)5:23 PM ET | Oct 23-24 | 5 daysLate | Plassche DouglasSVP of Operations | SSale | −1.13M | $0.4959 | −$562.3K | −100.0%0 after | 2 lots |